Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03297359
Other study ID # WAVe-001
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date March 21, 2018
Est. completion date November 30, 2023

Study information

Verified date January 2024
Source Ottawa Hospital Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cancer patients that develop blood clots are treated with low molecular weight heparin injections (LMWH). One kind of these LMWHs, dalteparin, has its dose determined based on a patient's weight using a formula of 200 international units (IU) per kilogram (kg). The current dosing of dalteparin approved by Health Canada has a maximum daily dose of 18 000 IU/day which is weight-adjusted for patients up to 90 kg. Any patient weighing more than 90 kg would take the same dosage regardless of their weight. The aim of this study is to assess the safety of using weight-adjusted dalteparin in cancer-associated venous thromboembolism patients that weigh more than 90 kg.


Description:

The study is designed as a multicentre prospective cohort study with multiple Canadian sites. It will be initiated at The Ottawa Hospital prior to being offered externally. After obtaining informed consent, and confirming eligibility, participants weighing more than 90 kg with acute cancer-associated thrombosis will be treated with therapeutic weight-adjusted dalteparin (subcutaneous once daily injection, or twice daily, if the conditions of the participant do not allow once daily injection as per clinical judgement) beginning at enrolment (within 12 hours) and continuing until Day 30 visit. Subjects will receive therapeutic doses of dalteparin at a dose of approximately 200 IU/kg SC daily (up to 33,000 IU) for one month. Following this study period of 30 days (± 4 days), patients will be followed for 5 months. During the follow-up period, each patient will pursue his/her treatment as per usual standard treatment protocols provided at each institution. Treatment used and clinical outcomes will be collected at the end of the follow-up period. The majority of Canadian Thrombosis specialists use weight adjusted dosing of dalteparin in patients weighing more than 90 kg with cancer-associated VTE. No expert recommends capping the dose of dalteparin to 18,000 IU in patients weighing over 90 kg as suggested by the product monograph. However, the risk of major bleeding episodes in patients over 90 kg receiving weight-adjusted LMWH remains unclear. The estimated rate of major bleeding episodes of patients with cancer associated VTE (Mean weight 79.1 kg) managed with therapeutic dose of dalteparin is 3.6% (95% CI: 1.9 to 6.2). We hypothesize that the rate of major bleeding events will be similar in patients (> 90 kg) with cancer-associated VTE treated with dalteparin 200 IU/kg daily (up to 33,000 IU). We plan to recruit 150 patients in this cohort study. We expect 6 major bleeding events. This would provide us with an overall bleeding event of 4% with an upper bound of the confidence interval of 8.5%). An informal survey of Canadian thrombosis expert has demonstrated that clinicians would feel reassured and continue to use weight-adjusted dalteparin in cancer patients weighing more than 90kg if the upper bound of the 95% confidence interval is less than 9% (i.e. < 3% possible absolute rate difference).


Recruitment information / eligibility

Status Terminated
Enrollment 92
Est. completion date November 30, 2023
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Known pathologically-confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin), 2. Confirmed symptomatic or incidental deep vein thrombosis requiring treatment, or confirmed symptomatic or incidental pulmonary embolism of a segmental or larger pulmonary artery, 3. Weight > 90 kg, 4. Age =18 years, 5. Hemoglobin = 80 g/L, 6. Able and willing to comply with study procedures and follow-up examinations contained within the written consent form. Exclusion Criteria: 1. Acute VTE managed with thrombectomy, insertion of an inferior vena cava filter or with the use of thrombolytic agents, 2. More than 72 hours pre-treatment with therapeutic dosage of other LMWH, direct oral anticoagulants or vitamin K antagonists prior to enrolment to manage the current VTE event (unless the participant has been treated with weight-adjusted doses of commercial dalteparin in consistency with the dosing regime outlined in the protocol up to Day 7 visit [±2 days]), 3. Contraindication to heparin therapy: 1. history of heparin induced thrombocytopenia (HIT) as reported by patient, 2. platelet count of less than 50 x 109/L, 3. actively bleeding, 4. reported history of severe uncontrolled hypertension, 5. documented peptic ulcer within 6 weeks, 6. reported history of severe hepatic failure, 7. creatinine clearance of < 30 ml/min as calculated by the Cockcroft-Gault formula, 8. heparin allergy, 9. Other contraindication to anticoagulation. 4. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or 4 at the time of study enrolment, 5. Life expectancy < 1 month, 6. Women of childbearing age without proper contraceptive measures and women who are pregnant or breast feeding, 7. Participating in another interventional trial that may result in co-intervention or contamination (to be determined by sponsor), 8. Unable/unwilling to provide informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Dalteparin
daily subcutaneous injection of weight-adjusted dalteparin

Locations

Country Name City State
Canada Alberta Health Services Edmonton Alberta
Canada Nova Scotia Health Authority Halifax Nova Scotia
Canada Juravinski Hospital Hamilton Ontario
Canada The Ottawa Hospital Ottawa Ontario
Canada Toronto General Hopsital Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major bleeding episode Fatal bleeding, and/or,
Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or,
Bleeding causing a fall in hemoglobin level of =20 g/L, or leading to transfusion of =2 units of whole blood or red cells.
up to day 30
Secondary Clinically relevant non major bleeding events As overt bleeding episodes not meeting the inclusion for major bleeding but associated with one of the following:
Medical intervention,
An unscheduled contact with a physician,
Temporary cessation of anticoagulant treatment.
up to day 30
Secondary Minor bleeding events Overt bleeding not meeting the major bleeding or clinically-relevant non-major bleeding definitions up to day 30
Secondary Recurrent VTE events Recurrent deep vein thrombosis
Recurrent Pulmonary embolism
Up to day 180
Secondary Overall mortality Death Up to day 180
Secondary Bioaccumulation of study drug Trough anti-Xa levels measured at Day 7 and Day 30 follow-up visits will be generated for the once and twice-daily dosing regimen Up to day 30
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2